|
[1] Guo Z S, Li Q, Bartlett D L, et al. Gene transfer: the challenge of regulated gene expression. Trends Mol Med. 2008,14(9):410-418.
[2] Stieger K, Belbellaa B, Le Guiner C, et al. In vivo gene regulation using tetracycline-regulatable systems. Adv Drug Deliv Rev. 2009, 61(7-8):527-541.
[3] Win M N, Liang J C, Smolke C D. Frameworks for programming biological function through RNA parts and devices. Chem Biol, 2009, 16:298-310.
[4] Buskirk A R, Landrigan A, Liu D R. Engineering a ligand-dependent RNA transcriptional activator. Chem Biol, 2004, 11:1157-1163.
[5] Chen Y Y, Jensen M C, Smolke C D. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc Natl Acad Sci USA, 2010,107:8531-8536.
[6] Win M N, Smolke C D. A modular and extensible RNA-based gene-regulatory platform for engineering cellular function. Proc Natl Acad Sci USA, 2007,104:14283-14288.
[7] Weigand J E, Suess B. Tetracycline aptamer-controlled regulation of pre-mRNA splicing in yeast. Nucleic Acids Res, 2007, 35:4179-4185.
[8] Kim D S, Gusti V, Dery K J, et al. Ligand-induced sequestering of branchpoint sequence allows conditional control of splicing. BMC Mol Biol, 2008, 9:23.
[9] Bayer T S, Smolke C D. Programmable ligand-controlled riboregulators of eukaryotic gene expression. Nat Biotechnol, 2005,23:337-343.
[10] Desai S K, Gallivan J P. Genetic screens and selections for small molecules based on a synthetic riboswitch that activates protein translation. J Am Chem Soc, 2004, 126:13247-13254.
[11] Suess B, Fink B, Berens C,et al. A theophylline responsive riboswitch based on helix slipping controls gene expression in vivo. Nucleic Acids Res, 2004,32:1610-1614.
[12] Sharma V, Nomura Y, Yokobayashi Y. Engineering complex riboswitch regulation by dual genetic selection. J Am Chem Soc, 2008,130:16310-16315.
[13] An C I, Trinh V B, Yokobayashi Y. Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA, 2006, 12:710-716.
[14] Beisel C L, Bayer T S, Hoff K G,et al. Model-guided design of ligand-regulated RNAi for programmable control of gene expression. Mol Syst Biol, 2008, 4:224.
[15] Beisel C L, Chen Y Y, Culler S J,et al. Design of small molecule-responsive microRNAs based on structural requirements for Drosha processing. Nucleic Acids Res, 2011,39(7):2981-2994.
[16] Yen L, Svendsen J, Lee J S, et al. Exogenous control of mammalian gene expression through modulation of RNA self-cleavage. Nature, 2004,431(7007):471-476.
[17] Yen L, Magnier M, Weissleder R, et al. Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA, 2006, 12: 797-806.
[18] Zamore P D, Haley B. Ribo-gnome: The big world of small RNAs. Science, 2005,309: 1519-1524.
[19] Lee S K, Kumar P. Conditional RNAi: towards a silent gene therapy. Adv Drug Deliv Rev, 2009, 61(7-8):650-664.
[20] Sandy P, Ventura A, Jacks T. Mammalian RNAi: A practical guide. Biotechniques, 2005, 39: 215-224.
[21] Tuleuova N, An C I, Ramanculov E, et al. Modulating endogenous gene expression of mammalian cells via RNA-small molecule interaction. Biochem Biophys Res Commun, 2008,376(1):169-173.
[22] Parrott C L, Alsayed N, Rebourcet R, et al. ApoC-IIParis2: a premature termination mutation in the signal peptide of apoC-II resulting in the familial chylomicronemia syndrome. J Lipid Res, 1992,33:361-367.
[23] Dranchak P K, Di Pietro E, Snowden A, et al. Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem, 2011,112(5):1250-1258.
[24] Floquet C, Deforges J, Rousset J P, et al. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res, 2011, 39(8):3350-3362.
[25] Murphy G J, Mostoslavsky G, Kotton D N, et al. Exogenous control of mammalian gene expression via modulation of translational termination. Nat Med, 2006, 12(9):1093-9109.
[26] Rothman J E. Mechanisms of intracellular protein transport. Nature, 1994,372:55-63.
[27] Dambach M D, Winkler W C. Expanding roles for metabolite-sensing regulatory RNAs. Curr Opin Microbiol, 2009, 12(2):161-169.
[28] Werstuck G, Green M R. Controlling gene expression in living cells through small molecule-RNA interactions. Science, 1998, 282:296-298.
[29] Han J, Xiong J, Wang D, et al. Pre-mRNA splicing: where and when in the nucleus. Trends Cell Biol, 2011, 21(6):336-343.
[30] Emanuele B, Francisco E B. Influence of RNA secondary structure on the pre-mRNA splicing process. Molecular and Cellular Biology, 2004, 24(24): 10505-10514.
[31] Kim D S, Gusti V, Dery K J, et al. Ligand-induced sequestering of branchpoint sequence allows conditional control of splicing. BMC Mol Biol, 2008, 9: 23.
[32] Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science,2003,302:415-419.
[33] Stoltenburg R, Reinemann C, Strehlitz B. SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng, 2007, 24:381-403.
[34] Sinha J, Reyes S J, Gallivan J P. Reprogramming bacteria to seek and destroy an herbicide. Nat Chem Biol, 2010, 6: 464-470.
[35] Lin J S, McNatty P K. Aptamer-based regionally-protected PCR for protein detection. Clin Chem, 2009, 55(9):1686-1693.
[36] Weigand J E, Schmidtke S R, Will T J, et al. Mechanistic insights into an engineered riboswitch: a switching element which confers riboswitch activity. Nucleic Acids Res, 2011, 39(8):3363-3372.
[37] Weigand J E, Sanchez M, Gunnesch E B, et al. Screening for engineered neomycin riboswitches that control translation initiation. RNA, 2008, 14: 89-97.
|
